Health ministry decides against including Itolizumab in clin
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The National Task Force on COVID-19 has decided against including Itolizumab drug in clinical management protocols for treating the disease even though the DCGI has approved its "restricted emergency use" in infected patients, official sources said.

The permission to market the drug was granted for the treatment of cytokine release syndrome in 'moderate' to 'severe' Acute Respiratory Distress Syndrome patients due to COVID-19.

"The issue of including the drug in the clinical protocols was discussed in a meeting held on 24 July. A majority of the members of the task force opined that there was not enough evidence currently to get the drug included in the clinical management protocols for COVID-19," said an official source.

However, a Biocon spokesperson said, "The National Covid Task Force needs to see more evidence and we will provide them large real-world data to enable the committee to reconsider its decision on inclusion of Itolizumab in the protocol."

"Nearly 1,000 patients have used the drug across the country with good outcome data," the company spokesperson said.

Source: https://health.economictimes.indiatimes.com/news/pharma/health-ministry-decides-against-including-itolizumab-in-clinical-management-protocols-for-covid-19/77187111
Dr. T●●●●z H●●●●●●i and 3 others like this
Like
Comment
Share